[A Prospective, Randomized Trial to Assess the Added Value of Concomitant Modulated Electro-hyperthermia in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy - an Investigator Initiated Study]
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 71
- 试验地点
- 2
- 主要终点
- Residual size of the primary tumor, determined by imaging techniques (in percentage)
研究概览
简要总结
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
详细描述
This study is a pivotal, randomized (1:1), open-label, two-treatment group, single-centre trial of Oncotherm EHY-2030, a modulated electro-hyperthermia (mEHT) device. Female patients aged 18 years or older with locally advanced, unilaterally localized HER2-negative breast cancer requiring neoadjuvant treatment are eligible for the study.
In the study, the wTAX (+ carboplatin) +AC neoadjuvant chemotherapy protocol will be administered according to the routine daily regimen, with or without mEHT three times a week during the wTAX (+ carboplatin) period. Carboplatin will be administered for patients with triple-negative breast cancer only.
Primary objective: to compare whether the percentage of tumor size decrease determined by imaging techniques is different in the two treatment groups?
Secondary and other objectives:
- Is complete pathological response (pCR) more common in the mEHT-treated group?
- Does the pattern of treatment response (pCR : pPR : pNR) differ between the two groups?
- Is the quality of life of patients different in the two study groups?
- Is there any treatment-related changes in the routine laboratory parameters such as blood count, liver enzymes, renal function? And do these differ in the two study arms?
- Safety and tolerability analysis of the device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age
- •Female patient
- •Life expectancy ≥ 6 months
- •De novo histological/cytological diagnosis of HER2-negative (triple-negative or ER/PR+) breast tumor involving one breast
- •Diagnosis of breast tumor ≤ 40 days
- •Locally advanced stage disease (stage II and III) requiring neoadjuvant treatment - according to the following criteria:
- •Primary breast tumor ≥ 20 mm in size and/or
- •Presence of axillary lymph node metastases
- •Optimal surgical intervention without neoadjuvant chemotherapy is not feasible
- •ECOG status: 0-2
- •Suitable for and designated by the investigator for neoadjuvant therapy with wTAX + (carboplatin) + AC chemotherapeutic agent
- •Willingness to participate in the trial and signed the informed consent form for the protocol
排除标准
- •Patient is ≤ 18 years of age.
- •Tumor of both breasts.
- •Diagnosis of breast tumor > 40 days
- •HER2 positive breast tumor
- •Has already received some anticancer therapy
- •Any previous cancer requiring anti-tumor treatment within 5 years prior to selection, except: in situ cervical or uterine cancer and non-melanoma skin cancer.
- •Co-existing serious diseases:
- •Presence of severe neuropathy requiring medical treatment, diabetic neuropathy.
- •Clinically significant hematological, hepatic or renal dysfunction, as defined below:
- •Neutrophil count < 1.5 G/L and platelet count < 100 G/L
- •bilirubin > 1.5 times the upper limit of normal range (ULN), except for known Gilbert's disease
- •AST and/or ALT > 2.5 times the upper limit of the normal range
- •Serum creatinine > 1.5 times the upper limit of the normal range.
- •Clinically significant cardiovascular disease in the medical history, unless the disease is adequately controlled. E.g. New York Heart Association (NYHA) Class II or worse congestive heart failure (moderate limitation of physical activity; well-being at rest but normal activity is associated with fatigue, rapid heart rate or dyspnoea).
- •Uncontrolled hypertension with resting systolic ≥ 180 mmHg, resting diastolic ≥ 110 mmHg.
- •Resting sinus tachycardia with a pulse ≥ 110/min.
- •History of sympathetic or treatment-naive cardiac arrhythmia. Atrial fibrillation or flutter controlled with medication is not an exclusion for participation in the study.
- •Major cardiovascular event (e.g. myocardial infarction, unstable angina, cerebral vascular accident (CVA), etc.) in the 6 months prior to randomisation.
- •Active infection or severe underlying disease that renders the patient unfit for treatment according to the study protocol.
- •A current diagnosis of chronic hepatitis, Hepatitis B surface antigen positive, Hepatitis C antibody positive and/or other clinically active liver disease requiring treatment.
- •Known HIV infection.
- •Untreated thyroid disease.
- •Systemic autoimmune disease.
- •Any psychiatric condition in the medical history that may result in the patient being unable to understand or comply with the requirements of the study, having reduced communication skills or being unable to give informed consent.
- •Need for concomitant anti-tumor therapy in addition to wTAX + (carboplatin) + AC protocol
- •Any active medical device implanted in the anatomical area, such as pacemakers.
- •Known severe hypersensitivity to any of the chemotherapies used in the study.
- •Pregnancy or breast-feeding (patients of childbearing potential must use effective contraception throughout the study and for 3 months after the end of treatment). The method of effective contraception is at the discretion of the investigator.
- •History of drug or alcohol dependence within 6 months prior to screening.
- •Unable to comply with the study plan for medical, psychological, family, geographical or other reasons.
- •Institutionalisation by administrative or judicial decision.
研究组 & 干预措施
wTAX (+ carboplatin) +AC
- wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
- AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
- Breast cancer tumor removal surgery (if feasible)
干预措施: Paclitaxel (Drug)
wTAX (+ carboplatin) +AC + mEHT
-
wTAX + mWEHT
-
wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
-
mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks
-
AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
-
Breast cancer tumor removal surgery (if feasible)
干预措施: Paclitaxel (Drug)
wTAX (+ carboplatin) +AC
- wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
- AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
- Breast cancer tumor removal surgery (if feasible)
干预措施: Cyclophosphamide/Doxorubicin (Drug)
wTAX (+ carboplatin) +AC
- wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
- AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
- Breast cancer tumor removal surgery (if feasible)
干预措施: Breast cancer removal surgery (Procedure)
wTAX (+ carboplatin) +AC + mEHT
-
wTAX + mWEHT
-
wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
-
mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks
-
AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
-
Breast cancer tumor removal surgery (if feasible)
干预措施: Oncotherm EHY-2030 (Device)
wTAX (+ carboplatin) +AC + mEHT
-
wTAX + mWEHT
-
wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
-
mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks
-
AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
-
Breast cancer tumor removal surgery (if feasible)
干预措施: Cyclophosphamide/Doxorubicin (Drug)
wTAX (+ carboplatin) +AC + mEHT
-
wTAX + mWEHT
-
wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
-
mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks
-
AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
-
Breast cancer tumor removal surgery (if feasible)
干预措施: Breast cancer removal surgery (Procedure)
wTAX (+ carboplatin) +AC
- wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
- AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
- Breast cancer tumor removal surgery (if feasible)
干预措施: Carboplatin (Drug)
wTAX (+ carboplatin) +AC + mEHT
-
wTAX + mWEHT
-
wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks
-
mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks
-
AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x
-
Breast cancer tumor removal surgery (if feasible)
干预措施: Carboplatin (Drug)
结局指标
主要结局
Residual size of the primary tumor, determined by imaging techniques (in percentage)
时间窗: change from baseline at 6 months
Using breast MR measurements, the the residual size of the primary tumor will be specified for all patients (in percentage). The comparison of these between the two study arms will serve as the primary outcome measure. Calculation: The tumor size after the 6-months treatment period (in mm) will be divided by the size measured prior treatment (in mm). The quotient will be given as a percentage and subtracted from 100.
次要结局
- Effect of treatment on hematocrit levels(through study completion, an average of ~8 months)
- Number of treatments where the planned power output of the Oncotherm EHY-2030 device could not be reached(3 months)
- Comparison of surgical procedure ratios(9 months)
- Percentage of complete pathological response(9 months)
- Effect of treatment on red blood cell counts(through study completion, an average of ~8 months)
- Effect of treatment on platelet counts(through study completion, an average of ~8 months)
- Effect of treatment on hemoglobin levels(through study completion, an average of ~8 months)
- Treatment response patterns(9 months)
- Longitudinal analysis of the EORTC QLQ-C30 questionnaire's total scores(through study completion, an average of ~8 months)
- Longitudinal analysis of the EORTC QLQ-BR23 questionnaire's total scores(through study completion, an average of ~8 months)
- Longitudinal analysis of the EQ-5D-5L questionnaire scores(through study completion, an average of ~8 months)
- Effect of treatment on white blood cell counts(through study completion, an average of ~8 months)
研究者
Marcell Szasz
Dr. A. Marcell Szasz, PhD, Head of Research at the Department of Internal Medicine and Oncology
Semmelweis University